In a vivid display of investor confidence, three firms across biotech and digital health have announced significant funding rounds that promise to accelerate innovation in their respective fields. Onchilles Pharma raised $25 million to advance its novel pan-cancer immunotherapy; Kailera Therapeutics captured a whopping $600 million Series B to power next-generation obesity treatments; and MiSalud Health secured a fresh injection of capital to scale its bilingual, culturally competent telehealth services for underserved workforces. These movers illustrate how strategic funding is catalysing breakthroughs across medical care and workforce health.
Onchilles Pharma Raises $25M in Series A1 Round
Onchilles Pharma has secured $25 million in a Series A1 funding round to advance its lead injectable candidate, N17350, targeting the ELANE enzyme for pan-cancer therapy. Backed by new investors including Invivium Capital, Kennedy Lewis Investment Management and UCM Ventures – alongside existing investors LYZZ Capital Advisors and Lincoln Park Capital Fund – the financing brings the biotech’s total Series A funding to $40 million. The firm also released preclinical data showing durable responses across 30 cancer cell lines, underscoring its ambition to shift the cancer treatment paradigm.
Kailera Therapeutics Inks $600M Series B to Drive Obesity Portfolio
Kailera Therapeutics, a clinical-stage biopharma company focused on next-generation obesity therapies, announced a $600 million Series B financing led by Bain Capital Private Equity. The funding will support the global Phase III programme for its lead asset, KAI-9531, an injectable dual GLP-1/GIP receptor agonist designed for best-in-class weight loss. Additional investors include Adage Capital, CPP Investments, Qatar Investment Authority, Royalty Pharma and others. With this capital infusion, Kailera is well positioned to scale its pipeline and compete in the booming obesity-therapy market.
MiSalud Health Boosts Bilingual Telehealth with Fresh Investment
MiSalud Health, a San Francisco-based digital health platform delivering culturally and linguistically competent care to bilingual workforces in sectors like agriculture, construction and hospitality, has raised $8 million. Led by Samsung Next and supported by Ulu Ventures, Magnify Ventures and Lowercase Capital, the investment will expand MiSalud’s workforce-focused bilingual telehealth services in the U.S. and Mexico. The company aims to narrow health-equity gaps by connecting Spanish-speaking workers with accessible virtual and onsite care delivered by culturally attuned professionals.
Share your Details for subscribe